ACR/ARP Medication Guide

AMERICAN COLLEGE of RHEUMATOLOGY Empowering Rheumatology Professionals

ASSOCIATION of RHEUMATOLOGY PROFESSIONALS

The Interprofessional Division of the American College of Rheumatology

Abaloparatide (Tymlos®)

Abaloparatide is an analog of human parathyroid hormone related peptide (PTHrP[1-34]), which acts as an agonist at the PTH1 receptor (PTH1R). This results in stimulation of osteoblast function and increased bone mass. Treatment with abaloparatide results in increased bone mineral density, bone mass, and strength

Resources from Manufacturer

Patient Medication Guide

Full Prescribing Information

Tymlos Co-pay Card

Radius Patient Assistance Application

FDA-Approved Indications and Dosing in Rheumatology

Abaloparatide is indicated for:

- Osteoporosis in females who are at high-risk for fracture or who have failed other options
- Males with primary osteoporosis at high risk for fracture

Subcutaneous Dosing

- 80mcg once daily
- Duration of therapy should generally not exceed 2 years
- After completion of therapy, switching to antiresorptive agent is necessary to maintain bone density gains
- Calcium and Vitamin D supplements are also recommended while receiving abaloparatide, and can be obtained over-the-counter as well as from food rich in these nutrients.

Contraindications

Known hypersensitivity to abaloparatide

Warnings and Precautions

- 1. Orthostatic hypotension: usually occurs within 4 hours of dose, within first several doses
- 2. Hypercalcemia: use with caution
- 3. Hypercalciuria and Urolithiasis: Monitor urine calcium if preexisting hypercalciuria or active urolithiasis are suspected
- 4. Should not be used in pregnancy

ACR/ARP Medication Guide

AMERICAN COLLEGE of RHEUMATOLOGY
Empowering Rheumasology Professionals

ASSOCIATION of
RHEUMATOLOGY
PROFESSIONALS
The Interprofessional Division of the
American College of Rheumatology

Adverse Reactions (≥2%)

- Hypercalciuria
- Dizziness
- Nausea
- Headache
- Palpitations
- Fatique
- Upper abdominal pain
- Vertigo

Medication Strength and Preparations

■ Supplied as 3120 mcg/1.56 mL injector pen

Medication Administration and Storage

- Store between 2°C to 8°C (36°F to 46°F) in the original cartons, protected from light. May be stored at room temperature at 20°C to 25°C (68°F to 77°F) for up to 30 days.
- Discard pen 30 days after first injection, even if it contains some unused solution

Subcutaneous Administration

- 1. Wash your hands prior to each injection
- 2. Remove medication from refrigerator and can administer medication immediately
- 3. Check medicine in cartridge, ensure medication is clear and colorless. Clean area to inject in periumbilical region
- 4. Pull off cap
- 5. Attach new needle and remove large needle cover
- 6. Remove small needle protector
- 7. Set dose to 80mcg, by turning knob of Tymlos pen clockwise until it stops. You will see "80" lined up in the dose display window
- 8. Hold Tymlos pen so you are able to see display window, insert pen straight into skin
- 9. Press the green injection button until it cannot go any further and the "0" is in the display window
- 10. Count to 10 to allow full dose of Tymlos to be given
- 11. Remove needle, put cap back on and return to refrigerator or keep at room temperature away from light

Note: If a dose is missed, resume injections as soon as you remember, do not inject 2 doses on the same day

Updated June 2024–ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is offered solely for purposes of providing health care professionals with a quick and initial reference. Before prescribing or administering any drug contained in this biologic reference guide, health professionals should read the manufacturer's complete prescribing information in order to be informed of the various clinical considerations to be taken into account. The American College of Rheumatology is providing this information as a benefit and service in furtherance of its educational mission. By providing this information, ACR is not endorsing or recommending any of the listed companies or any of their drugs or other products. The information contained in the biologic reference guides reflect the conclusions of the individual companies and not those of the ACR which specifically disclaims any responsibility or liability for the use of such information and/or for the performance of any of the drugs listed in this biologic reference guide.